GSK’s IO Backbone Jemperli Looks Stronger After OS Success

Jemperli has struggled to gain a presence in cancer immunotherapy so far, but GSK believes the PD-1 therapy can hold its own against Merck & Co’s mega-blockbuster Keytruda in a few key areas.